• Corpus ID: 35394328

[The effect of benzbromarone on hyperlipidemia in gout].

@article{Marinchev1990TheEO,
  title={[The effect of benzbromarone on hyperlipidemia in gout].},
  author={Lyubomir Marinchev and K. Kunev},
  journal={Vutreshni bolesti},
  year={1990},
  volume={29 5},
  pages={
          99-102
        }
}

• L. Marinchev, K. Kunev
• Published 1990
• Medicine
• Vutreshni bolesti

It is well known that triglycerides and cholesterol are often increased in gout. In 50% of the patients with hyperuricemia and in 40% of the patients with gout hyperlipidemia is found. K. Kŭnev has found in his former studies that the treatment with the drug Desuric leads to a decrease of cholesterol and other lipids in the blood. The follow up of 38 men with proved gout, mean age 45 years and mean duration of the disease 5 years, established an increase mainly of endogenous triglycerides and cholesterol. Benzbromarone treatment, 50-100 mg daily, led to a parallel decrease of serum lipids and uric acid. This allows benzbromarone to be recommended for the treatment of hyperlipidemia in gout which will lead to a decrease of the vascular complications and mortality in gout.